{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:02:49Z","timestamp":1790920969483,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1053\/j.gastro.2011.12.060","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T08:08:59Z","timestamp":1335254939000},"page":"1369-1372","source":"Crossref","is-referenced-by-count":11,"title":["Is Hepatitis Virus Resistance to Antiviral Drugs a Threat?"],"prefix":"10.1053","volume":"142","author":[{"given":"Jean\u2013Michel","family":"Pawlotsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2011.12.060_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"Clavel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2011.12.060_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/368083","article-title":"Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B","volume":"36","author":"Lai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2011.12.060_bib3","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2011.12.060_bib4","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","article-title":"Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients","volume":"133","author":"Lampertico","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2011.12.060_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12072-010-9243-x","article-title":"De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients","volume":"5","author":"Wang","year":"2011","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2011.12.060_bib6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure","volume":"48","author":"Villet","year":"2008","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2011.12.060_bib7","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(09)60022-2","article-title":"Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients","volume":"50","author":"Tenney","year":"2009","journal-title":"J Hepatol"},{"issue":"Suppl","key":"10.1053\/j.gastro.2011.12.060_bib8","first-page":"480A","article-title":"No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment","volume":"54","author":"Marcellin","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2011.12.060_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2011.12.060_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2011.12.060_bib11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2011.12.060_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1053\/j.gastro.2011.12.060_bib13","first-page":"189","article-title":"Genetic heterogeneity and properties of hepatitis C virus","volume":"61","author":"Pawlotsky","year":"1998","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1053\/j.gastro.2011.12.060_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2011.12.060_bib15","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(11)60069-X","article-title":"Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations","volume":"54","author":"Chevaliez","year":"2011","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2011.12.060_bib16","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1053\/j.gastro.2011.12.060_bib17","first-page":"430A","article-title":"HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon\/ribavirin when retreated with boceprevir plus PegIntron (peginterferon alfa-2b)\/ribavirin","volume":"52","author":"Bacon","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2011.12.060_bib18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2011.12.060_bib19","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1053\/j.gastro.2011.12.060_bib20","first-page":"436A","article-title":"Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study","volume":"52","author":"Zeuzem","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2011.12.060_bib21","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/S0168-8278(11)61358-5","article-title":"Quadruple therapy with BMS-790052, BMS-650032 and peg-IFN\/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders","volume":"54","author":"Lok","year":"2011","journal-title":"J Hepatol"},{"issue":"Suppl","key":"10.1053\/j.gastro.2011.12.060_bib22","first-page":"1428A","article-title":"Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders","volume":"54","author":"Chayama","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1053\/j.gastro.2011.12.060_bib23","first-page":"377A","article-title":"Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3","volume":"54","author":"Gane","year":"2011","journal-title":"Hepatology"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508512002181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508512002181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T22:27:43Z","timestamp":1543012063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508512002181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0016508512002181"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2011.12.060","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}